Free Trial
NASDAQ:ZURA

Zura Bio (ZURA) Stock Price, News & Analysis

Zura Bio logo
$2.30 +0.02 (+0.88%)
(As of 11:09 AM ET)

About Zura Bio Stock (NASDAQ:ZURA)

Key Stats

Today's Range
$2.19
$2.35
50-Day Range
$2.20
$4.92
52-Week Range
$2.00
$6.35
Volume
207,480 shs
Average Volume
345,029 shs
Market Capitalization
$150.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.80
Consensus Rating
Buy

Company Overview

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Zura Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
65th Percentile Overall Score

ZURA MarketRank™: 

Zura Bio scored higher than 65% of companies evaluated by MarketBeat, and ranked 367th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zura Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Zura Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Zura Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Zura Bio are expected to decrease in the coming year, from ($0.65) to ($0.87) per share.

  • Price to Book Value per Share Ratio

    Zura Bio has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.97% of the float of Zura Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Zura Bio has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zura Bio has recently increased by 4.03%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Zura Bio does not currently pay a dividend.

  • Dividend Growth

    Zura Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.97% of the float of Zura Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Zura Bio has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zura Bio has recently increased by 4.03%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Zura Bio has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • Search Interest

    2 people have searched for ZURA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Zura Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zura Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,734,458.00 in company stock.

  • Percentage Held by Insiders

    22.10% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zura Bio's insider trading history.
Receive ZURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter.

ZURA Stock News Headlines

Leerink Partnrs Predicts Increased Earnings for Zura Bio
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
Zura Bio submits protocol to FDA for Phase 2 study of Tibulizumab
Zura Bio Limited: Q3 2024 Financial Insights and Strategic Progress
See More Headlines

ZURA Stock Analysis - Frequently Asked Questions

Zura Bio's stock was trading at $4.67 at the beginning of 2024. Since then, ZURA shares have decreased by 51.2% and is now trading at $2.28.
View the best growth stocks for 2024 here
.

Zura Bio Limited (NASDAQ:ZURA) announced its earnings results on Thursday, November, 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.12.

Zura Bio's top institutional investors include Great Point Partners LLC (4.86%), Braidwell LP (3.68%), Geode Capital Management LLC (1.36%) and Sphera Funds Management LTD. (1.10%). Insiders that own company stock include Someit Sidhu, Van Amstel Arnout Ploos, Michael Howell, Kiran Nistala and Parvinder Thiara.
View institutional ownership trends
.

Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zura Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walt Disney (DIS).

Company Calendar

Last Earnings
11/07/2024
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZURA
Web
N/A
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.80
High Stock Price Target
$26.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+587.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-69,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.85 per share

Miscellaneous

Free Float
50,864,000
Market Cap
$150.18 million
Optionable
Optionable
Beta
-0.02
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:ZURA) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners